
Evogene Ltd.
EVGNNASDAQHealthcareBiotechnology
Previous close
$0.5625
+$0.002 · +0.36%
EVGN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
29
Expensive
Momentum
20
Strong Down
Sentiment
60
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEvogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Ofer Haviv
- Listed since
- Oct 15, 2010
- Employees
- 52
Market position
Day range
Current $0.5625
52-week range
Current $0.5625
- Open
- $0.5437
- Previous close
- $0.5605
- Volume
- 1.04M
- 0.78× average
- Average volume
- 1.33M
- Average daily volume
- Market cap
- 4.85M USD
- Beta
- 0.78
- Market reference 1
- 50-day average
- $0.5336
- +5.42% above average
- 200-day average
- $0.8247
- -31.79% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -2.1M USD
- P/E (TTM)
- -0.63×
- P/B (TTM)
- -2.16×
- P/S (TTM)
- 3.82×
- EV / EBITDA
- 0.17×
- Earnings yield
- -97.96%
- Free cash flow yield
- -157.44%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -14.16%
- Operating margin
- -1020.35%
- Net margin
- -696.26%
- Return on equity
- 10347.56%
- Return on assets
- -42.33%
- Return on invested capital
- -81.04%
Financial health
- Debt / equity
- -0.64×
- Current ratio
- 4.54×
- Altman Z-score
- -32.1
- Piotroski F-score
- 1 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.85M USD | 5.58M USD | 2.98M USD | 1.68M USD | 930K USD |
| Cost of goods sold | 4.09M USD | 2.38M USD | 1.49M USD | 909K USD | 767K USD |
| Gross profit | −241K USD | 3.2M USD | 1.49M USD | 766K USD | 163K USD |
| Research and development | 7.99M USD | 12.51M USD | 16.2M USD | 20.79M USD | 21.13M USD |
| Selling, general, and administrative | 5.76M USD | 8.98M USD | 7.53M USD | 10.42M USD | 9.99M USD |
| Operating expenses | 13.79M USD | 22M USD | 23.72M USD | 27.71M USD | 31.12M USD |
| Interest income | 2.47M USD | 957K USD | 1.25M USD | 182K USD | 291K USD |
| Interest expense | 1.89M USD | 124K USD | 171K USD | 241K USD | 403K USD |
| Depreciation and amortization | 1.14M USD | 1.38M USD | 1.3M USD | 2.58M USD | 2.23M USD |
| Operating income | −14.03M USD | −18.8M USD | −22.23M USD | −26.94M USD | −30.95M USD |
| Net income | −8.49M USD | −16.49M USD | −23.88M USD | −26.64M USD | −27.79M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -151.81%
- 11 comparable reports
- Latest EPS result
- -0.13
- Estimate -0.27 · Beat by 51.85%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$2.15
282.22% upsidePrice history unavailable
High $2.15Average $2.15Low $2.15EVGN news
EVGN peers
Continue in GoAI
Research EVGNresearch.disclaimer











